Trade Lyell Immunopharma, Inc. - LYEL CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.26 |
| Open | 1.22 |
| 1-Year Change | -43.78% |
| Day's Range | 1.13 - 1.22 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 6, 2024 | 1.14 | -0.07 | -5.79% | 1.21 | 1.24 | 1.13 |
| Sep 5, 2024 | 1.26 | -0.06 | -4.55% | 1.32 | 1.35 | 1.26 |
| Sep 4, 2024 | 1.35 | 0.00 | 0.00% | 1.35 | 1.40 | 1.32 |
| Sep 3, 2024 | 1.37 | -0.06 | -4.20% | 1.43 | 1.48 | 1.35 |
| Aug 30, 2024 | 1.43 | 0.03 | 2.14% | 1.40 | 1.47 | 1.40 |
| Aug 29, 2024 | 1.43 | 0.01 | 0.70% | 1.42 | 1.50 | 1.42 |
| Aug 28, 2024 | 1.43 | 0.03 | 2.14% | 1.40 | 1.49 | 1.40 |
| Aug 27, 2024 | 1.43 | -0.10 | -6.54% | 1.53 | 1.53 | 1.40 |
| Aug 26, 2024 | 1.56 | 0.07 | 4.70% | 1.49 | 1.58 | 1.47 |
| Aug 23, 2024 | 1.53 | 0.13 | 9.29% | 1.40 | 1.59 | 1.40 |
| Aug 22, 2024 | 1.43 | -0.01 | -0.69% | 1.44 | 1.45 | 1.41 |
| Aug 21, 2024 | 1.43 | 0.04 | 2.88% | 1.39 | 1.47 | 1.39 |
| Aug 20, 2024 | 1.43 | 0.06 | 4.38% | 1.37 | 1.46 | 1.36 |
| Aug 19, 2024 | 1.43 | 0.25 | 21.19% | 1.18 | 1.44 | 1.18 |
| Aug 16, 2024 | 1.19 | -0.03 | -2.46% | 1.22 | 1.27 | 1.19 |
| Aug 15, 2024 | 1.23 | 0.04 | 3.36% | 1.19 | 1.27 | 1.17 |
| Aug 14, 2024 | 1.17 | -0.16 | -12.03% | 1.33 | 1.36 | 1.17 |
| Aug 13, 2024 | 1.35 | 0.00 | 0.00% | 1.35 | 1.36 | 1.32 |
| Aug 12, 2024 | 1.33 | -0.04 | -2.92% | 1.37 | 1.40 | 1.32 |
| Aug 9, 2024 | 1.51 | 0.02 | 1.34% | 1.49 | 1.54 | 1.42 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Lyell Immunopharma, Inc. Company profile
About Lyell Immunopharma Inc
Lyell Immunopharma, Inc is a T cell reprogramming company. The Company offers T cells to cure patients with solid tumors. Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. It builds a multi-modality product pipeline across solid tumor indications with unmet needs and anticipate having investigational new drug application (IND). It offers Gen-R and Epi-R technology platforms. Its Gen-R is its ex vivo genetic reprogramming technology to overcome T cell exhaustion. Its Epi-R is an ex vivo epigenetic reprogramming technology to create a population of T cells with durable stemness. Epi-R is designed to generate populations of T cells which have this property of durable stemness. It utilizes its Gen-R and Epi-R technology platforms to develop a multi-modality product pipeline.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Lyell Immunopharma Inc revenues increased 44% to $7.8M. Net loss increased 1% to $166.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $11.3M to $28.4M (expense), General and administrative - Balanc increase of 39% to $28.8M (expense).
| Industry: | Bio Therapeutic Drugs |
201 Haskins Way
Suite 301
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024
European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024
Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024
FOMC PREVIEW
Markets believe the Federal reserve will continue to leave their monetary policy unchanged at the meeting next week.
14:09, 1 August 2024
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com